Phase 2 Study of Iadademstat in Patients with Essential Thrombocythemia Resistant or Intolerant to Hydroxyurea
- Trial ID
- 2025-523864-19-00
- Protocol
- CL06-ORY-1001
- Sponsor
- Oryzon Genomics S.A.
Trial statistics
Diseases & Conditions
Objectives
The primary objective of this phase 2 study is to evaluate the efficacy of iadademstat by measuring the reduction in the percentage of adult patients with essential thrombocythemia presenting with abnormal platelet counts. Additionally, the investigation aims to assess the safety and tolerability of the study drug in this patient population. The assessment includes the evaluation of pharmacokinetics and pharmacodynamics.
Participants
The sponsor did not provide information regarding the total number of participants. The study population consists of adult patients with essential thrombocythemia. Eligible participants include individuals aged 18 years or older with a body weight of at least 50 kg. Inclusion requires a diagnosis of high-risk disease according to IPSET-t diagnostic criteria and a prior history of hydroxyurea treatment with documented intolerance or inadequate response. Required hematologic parameters include a platelet count greater than 450×10⁹/L, an absolute neutrophil count ≥ 0.5×10⁹/L, and hemoglobin ≥ 10 g/dL. Furthermore, patients must exhibit a fibrosis score of less than grade 2 based on modified European Consensus Criteria. The study objectives are:
- To evaluate the efficacy of iadademstat in reducing the percentage of patients with abnormal platelet counts.
- To evaluate the safety and tolerability of the investigational treatment.
Plans and Procedures
This Phase 2 clinical trial is designed to evaluate the efficacy and safety of iadademstat in adult patients diagnosed with essential thrombocythemia who are resistant or intolerant to hydroxyurea. The study aims to determine the percentage of patients achieving a reduction in platelet counts to ≤400×10⁹/L without subsequent thrombotic events and to monitor the occurrence and severity of treatment-emergent adverse events. The research methodology involves several stages, beginning with a screening visit to confirm eligibility through bone marrow evaluation, peripheral blood sampling, and assessment of fibrosis scores. Following enrollment, participants will receive iadademstat as an oral solution. Study procedures include periodic monitoring of hematological parameters. Bone marrow evaluations are required at screening and may be conducted at week 48 during the extension phase or as medically indicated. The primary efficacy endpoint is assessed during a 24-week treatment period. Participation may be subject to early termination based on medical necessity or clinical requirements.
Treatment
The experimental medication is iadademstat, administered as an oral solution. The substance is intended for oral use.
Efficacy
The efficacy of iadademstat in patients with essential thrombocythemia will be evaluated by determining the percentage of adult subjects achieving a reduction in platelet counts to ≤400x10⁹/L. This endpoint requires the achievement of normal platelet counts in the absence of subsequent thrombotic events at any time during 24 weeks of treatment.
Inclusion and Exclusion Criteria
Inclusion Criteria
- Age ≥ 18 years
- Body weight of at least 50 kg
- Diagnosis of ET per revised WHO 2016 with High-risk per the revised IPSET-t diagnostic criteria for myeloproliferative neoplasms (either thrombosis history at any age or JAK2-mutated patients who are > 60 years old before treatment starts)
- Patients who had previously been treated with HU and are intolerant to HU or had inadequate response as per the European Leukemia Net (ELN) criteria: • Platelet count > 600×109/L after a daily dose of at least 2g HU for at least 3 months (2.5 g/day in patients with a body weight over 80 kg) or maximally tolerated dose if < 2g/day after at least 3 months of HU • Platelet count > 400 × 109/L and WBC < 2.5 ×109/L at any dose and duration of HU • Platelet count > 400 × 109/L and hemoglobin < 10 g/dL at any dose and duration of HU • Presence of HU-non hematologic related toxicities at any dose and duration of therapy (e.g., fever, pneumonitis, mucocutaneous manifestations or leg ulcers)
- Must have discontinued previous ET therapy at least for: • 24h if prior anagrelide or hydroxyurea • 4 weeks if prior interferon • 7 days for all other prior therapies
- Blood parameters pre-dose at screening should be: • Platelet count > 450x109/L • ANC ≥ 0.5x109/L • Hb ≥ 10g/dL CONFIDENTIAL 15 • Peripheral blast count < 1%
- Fibrosis Score < grade 2, as per a slightly modified version of the European Consensus Criteria for Grading Myelofibrosis [MF-0 or MF-1 fibrosis consistent with low-grade reticulin deposition and prefibrotic myelofibrosis]
- Life expectancy > 9 months
- Able to swallow oral medications
- Able and willing to give consent and comply with all study procedures including bone marrow (BM) evaluation and peripheral blood (PB) sampling during the study [BM is only required at screening and week 48 of treatment for those patients in the extension phase or as medically indicated]
- Women of childbearing potential, must have a documented negative pregnancy test prior to entry and agree to use one or more locally medically accepted methods of contraception from consent, through the entire study period and 4 months after last dose of iadademstat
- Men of reproductive capacity must agree to use effective contraception from the start of treatment through 4 months after last dose of iadademstat
- Agreement to not to donate or freeze egg(s) or sperm during the course of this study or within 4 months after receiving their last dose of study drug
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible
Exclusion Criteria
- Transfusion dependency, defined as requiring 2 or more units of packed red blood cells (RBC) per month for more than 3 months or a hemoglobin level of ≤ 8g/dL in the preceding 8 weeks before the start of dosing
- Eastern Cooperative Oncology Group (ECOG) questionnaire score of 3 or greater at Screening
- History of splenectomy
- Has undergone major surgery ≤4 weeks prior to starting study drug or has not recovered from the side effects of such surgery
- Unresolved treatment-related toxicities from prior therapies (unless resolved to ≤ Grade 1)
- Evidence at the time of Screening of increased risk of bleeding, including any of the following: • Activated partial thromboplastin time (aPTT) > 1.3 x the upper limit of normal (ULN) • International normalized ratio (INR) > 1.3 x the local ULN • History of severe thrombocytopenia or platelet dysfunction unrelated to a myeloproliferative disorder or its treatment • Known bleeding disorder (e.g., dysfibrinogenemia, factor IX deficiency, hemophilia, Von Willebrand’s disorder (e.g. patients diagnosed with Acquired von Willebrand syndrome [AVWS]), Disseminated Intravascular Coagulation [DIC], fibrinogen deficiency, or other clotting factor deficiency)
- Evidence at the time of Screening of significant renal or hepatic insufficiency as defined by any of the following local lab parameters: • Calculated glomerular filtration rate (GFR; using the Cockcroft-Gault equation) < 40 mL/min/1.73 m2 or serum creatinine > 1.5 x ULN • Aspartate transaminase (AST) or alanine aminotransferase (ALT) ≥2 x ULN • Bilirubin > 1.5 x ULN Total and direct bilirubin > 3 x ULN, if the elevation is associated with choledocholithiasis, cholecystitis, biliary obstruction, or hepatocellular disease. Elevated bilirubin attributed to hemolysis or Gilbert’s syndrome is not exclusionary • History of cirrhosis or any evidence of bridging fibrosis, or active hepatitis on liver biopsy
- Uncontrolled active infection (bacterial, viral, fungal, or parasitic) in the last 72h before starting study treatment
- Known fever > 38.5°C in the week prior to first administration of study medication
- Current diagnosis of pulmonary hypertension requiring oxygen therapy
- Congestive heart failure New York Heart Association (NYHA) class 3 or 4
- Left ventricular ejection fraction (LVEF) < 45% by echocardiogram or MUGA
- Mean of triplicate corrected QT interval (mQTcF) > 450ms at Screening
- Uncontrolled or untreated infection with Human immunodeficiency virus (HIV) or hepatitis B or C virus (HBV, HCV) • HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial • For patients with evidence of chronic HBV infection, the HBV viral load must be undetectable on suppressive therapy to be eligible for this trial • History of HCV infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
- Current use of prohibited medication (i.e., cytotoxic agents, hematopoietic growth factors, monoamine oxidase A and B inhibitors (MAOIs) like Tranylcypromine or Phenelzine) or expected to require any of these medications during treatment with the investigational drug. Previous use requires a washout period at least 5 half-lives of that agent or 14 days if half-live unknown prior to the study D1
- Known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to drugs chemically related to MAOIs
- History of any illness/impairment of gastrointestinal (GI) function that might interfere with drug absorption (e.g., chronic diarrhea, patients with gastric bypass)
- Prior use of an investigational agent requires a washout period of at least 5 half-lives of that agent or 14 days if half-live unknown, prior to the study D1
- Patients refractory to bomedemstat or other LSD-1 inhibitors for the treatment of ET
- Patients with known sensitivity to iadademstat
- Known current drug or alcohol abuse
- Other co-morbidity that substantially increases subject's risk for the study per the Investigator discretion. Subjects with a concurrent second active but stable malignancy, such as non-melanoma skin cancers, are eligible
- Currently pregnant or breastfeeding or plan to become pregnant or breastfeed during the study
- Unable to comply with the study procedures outlined in the protocol as judged by the investigator
- Patients may not receive administration of live or live-attenuated vaccines. Administration of non-live vaccines including RNA- based vaccines is allowed and is recommended for pneumococcal, coronavirus and influenza vaccines
Trial Status by Country
| Country | Status | Start of Recruitment | Planned Patients |
|---|---|---|---|
 Spain | Recruiting | 31 Mar 2026 | 36 |